• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Oscar Health Stock In Focus After Profit Turnaround And Raised Outlook

    Simply Wall St·11/07/2026 08:32:48
    Listen to the news
    • Oscar Health reported Q3 2026 revenue of US$5.14b and net income of US$167.28m, reversing a loss a year earlier and raising full year 2026 revenue and earnings from operations guidance.
    • The insurer paired this profit turnaround with expanding membership and footprint, suggesting its technology led pricing and medical cost controls are starting to scale across a larger book of business.
    • We will look at how Oscar Health's investment narrative shifts as stronger earnings guidance intersects with its AI driven insurance model.

    See how Oscar Health’s AI driven insurance pivot compares with other potential breakouts in the sector by reviewing our hand picked list of 35 healthcare AI stocks

    Oscar Health Investment Narrative Recap

    For a shareholder, the big idea in Oscar Health is simple. You need to trust that its AI native platform and disciplined pricing can keep turning membership growth into sustainable profits while holding medical and operating costs in check. The Q3 profit and nine month net income of US$1,208.09m support that thesis but do not remove execution risk.

    The key near term catalyst is whether Oscar Health can keep its medical loss ratio and SG&A trending in line with the margin story management has outlined. The biggest risk is that ACA market growth or utilization trends break from assumptions, which could pressure those targets even if the technology stack performs as planned.

    The raised 2026 guidance looks most relevant here. Management now expects full year revenue of US$19.0b to US$19.3b and earnings from operations of US$850m to US$950m, up from US$600m to US$800m. That update ties directly to the operating thesis that Oscar Health’s pricing discipline and AI driven cost controls are scaling.

    For you, that guidance bump turns into a live test of execution. The focus over the next few quarters is whether risk adjustment, Lucie marketplace traction and ACA plus CHOICE membership can support those higher operating earnings without medical costs drifting higher. Any sign of expense creep or regulatory friction would quickly challenge that raised outlook.

    What The Current Forecasts Assume For Oscar Health

    Oscar Health's current analyst narrative anchors on revenue of US$27.7b and earnings of US$1.2b by 2029. That profile rests on forecast revenue growth of 21.9% a year and an earnings increase of roughly US$649.3m from US$550.7m today.

    Uncover why Oscar Health's fair value indicates a 19% potential upside to its current price, which could narrow quickly.

    NYSE:OSCR 1-Year Stock Price Chart
    NYSE:OSCR 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish twist on Oscar Health focuses on Lucie and other AI marketplaces as the real earnings swing factor. The most optimistic analysts were already pencilling in about US$30.4b of revenue and US$1.3b of earnings by 2029 before this latest profit jump. You can treat today’s raised guidance as a fresh chance to compare that upbeat scenario with more cautious views and decide which story fits your expectations.

    Explore 5 other Oscar Health fair value estimates, including one that suggests as much as 1803% upside from the current price!

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Oscar Health?

    If this Oscar Health update has sharpened your view on what you want from a stock, it can help to scan the market for other companies that match those priorities using the Simply Wall St Screener.